PMID- 25889322 OWN - NLM STAT- MEDLINE DCOM- 20160108 LR - 20240322 IS - 1478-6362 (Electronic) IS - 1478-6354 (Print) IS - 1478-6354 (Linking) VI - 17 IP - 1 DP - 2015 Mar 10 TI - Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. PG - 51 LID - 10.1186/s13075-015-0557-x [doi] LID - 51 AB - INTRODUCTION: Intra-articular injection of hyaluronic acid (HA) is often used as therapy for knee osteoarthritis because it is less expensive and less aggressive than total knee replacement. Therefore, it is important to document whether HA is safe and efficacious. We tested whether single and multiple injection viscosupplementation with HA is associated with clinically meaningful pain relief in a new randomized clinical trial (RCT). Our objective was to compare safety and efficacy of intra-articular HA in two formulations: one 3.0 ml injection of Durolane versus five 2.5 ml injections of Artz for the treatment of knee osteoarthritis pain. METHODS: Patients (N=349) from the People's Republic of China were randomized to treatment (Durolane=175, Artz=174). The Durolane group received a 3.0 ml injection at week 0 (baseline), with sham skin punctures at weeks 1, 2, 3, and 4. The Artz group received one 2.5 ml injection at each of the same time points. The primary assessment tool was the Likert-type Western Ontario and McMaster University (WOMAC) pain scale at weeks 0, 6, 10, 14, 18, and 26. Secondary assessments were WOMAC physical function, knee stiffness, and global self-assessment, at identical time points. Statistically-controlled analyses were non-inferiority of Durolane over 18, then over 26 weeks, with a priori non-inferiority defined as 8% of the relevant scale. Acetaminophen was permitted as rescue analgesia and all adverse events (AEs) were recorded. RESULTS: Overall study retention was excellent; 332 patients (95.1%) completed 18 weeks and 319 (91.4%) completed 26 weeks, with no significant retention difference between treatment arms. All variables met non-inferiority criteria over 18 and 26 weeks. Efficacy response in both arms was >90%. Treatment-related AEs were 9.8% (17/174) for Artz and 13.1% (23/175) for Durolane. CONCLUSIONS: A single injection of Durolane is non-inferior to 5 injections of Artz over 18 and 26 weeks for pain, physical function, global self-assessment, and knee stiffness. Both treatments were efficacious, safe, and well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov NCT01295580 . Registered 11 February 2011. FAU - Zhang, Heng AU - Zhang H AD - Arthritis Clinic & Research Center, Peking University People's Hospital, 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. 469325342@qq.com. FAU - Zhang, Ke AU - Zhang K AD - Department of Orthopedics, Peking University Third Hospital, Beijing, China. zhangke60@medmail.com.cn. FAU - Zhang, Xianlong AU - Zhang X AD - Department of Orthopedics, Shanghai 6th People's Hospital, Shanghai, China. zxl40@vip.sina.com. FAU - Zhu, Zhenan AU - Zhu Z AD - Department of Orthopedics, Shanghai 9th People's Hospital, Shanghai, China. zhuzhenan2006@126.com. FAU - Yan, Shigui AU - Yan S AD - Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Province, China. zrjwsj@zju.edu.cn. FAU - Sun, Tiansheng AU - Sun T AD - Department of Orthopedics, Beijing Military General Hospital, Beijing, China. suntiansheng_@163.com. FAU - Guo, Ai AU - Guo A AD - Department of Orthopedics, Beijing Friendship Hospital, Beijing, China. guoaij@yahoo.com.cn. FAU - Jones, John AU - Jones J AD - Bioventus LLC, Durham, NC, USA. John.Jones@bioventusglobal.com. FAU - Steen, R Grant AU - Steen RG AD - Bioventus LLC, Durham, NC, USA. Grant.Steen@bioventusglobal.com. FAU - Shan, Bin AU - Shan B AD - TigerMed Consulting Co., Ltd, Beijing, China. bin.shan@tigermed.net. FAU - Zhang, Jenny AU - Zhang J AD - TigerMed Consulting Co., Ltd, Beijing, China. jenny.zhang@tigermed.net. FAU - Lin, Jianhao AU - Lin J AD - Arthritis Clinic & Research Center, Peking University People's Hospital, 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. linjianhao@pkuph.edu.cn. LA - eng SI - ClinicalTrials.gov/NCT01295580 PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20150310 PL - England TA - Arthritis Res Ther JT - Arthritis research & therapy JID - 101154438 RN - 0 (Adjuvants, Immunologic) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Adult MH - Aged MH - Dose-Response Relationship, Drug MH - Female MH - Follow-Up Studies MH - Humans MH - Hyaluronic Acid/*administration & dosage MH - Injections, Intra-Articular MH - Knee Joint MH - Male MH - Middle Aged MH - Osteoarthritis, Knee/*drug therapy MH - Prospective Studies MH - Treatment Outcome PMC - PMC4391669 EDAT- 2015/04/19 06:00 MHDA- 2016/01/09 06:00 PMCR- 2015/03/10 CRDT- 2015/04/19 06:00 PHST- 2014/08/27 00:00 [received] PHST- 2015/02/16 00:00 [accepted] PHST- 2015/04/19 06:00 [entrez] PHST- 2015/04/19 06:00 [pubmed] PHST- 2016/01/09 06:00 [medline] PHST- 2015/03/10 00:00 [pmc-release] AID - 10.1186/s13075-015-0557-x [pii] AID - 557 [pii] AID - 10.1186/s13075-015-0557-x [doi] PST - epublish SO - Arthritis Res Ther. 2015 Mar 10;17(1):51. doi: 10.1186/s13075-015-0557-x.